←
Boris Hadaschik606 posts
Boris Hadaschik avatar✓

Boris Hadaschik ✓

@ProfHadaschik

Urologic oncologist & surgeon; Chairman, Department of Urology, Pediatric Urology and Urooncology, University Hospital Essen

◷ Joined October 2018▧ 11 Photos and videos
Boris Hadaschik avatar
Boris Hadaschik@ProfHadaschik·May 31

To cure a larger fraction of patients with high risk disease we will need a truly integrated approach. I am surpised that there was not more salvage RT in PROTEUS.

Boris Hadaschik avatar
Boris Hadaschik@ProfHadaschik·May 31

It adds data to the discussion. The RP only substudy comes next year. SPCG15 will be very important. Primary PET staging not available in PROTEUS. Comparison to ENZARAD and ATLAS will be interesting… I am very happy that PROTEUS is positive.

Advanced Prostate Cancer Consensus Conference avatar
⟳ Boris Hadaschik retweeted
Advanced Prostate Cancer Consensus Conference@APCCC_Lugano·Mar 13

New prostate cancer risk groups by PSMA-PET (PPP3): an international, retrospective, registry-based cohort study thelancet.com/journals/lanon… In an international registry study of 11,154 patients, investigators developed PPP3 nomograms integrating clinical features and PSMA-PET PROMISE metrics to predict 3-, 5-, and 7-year overall survival in #ProstateCancer Developed and validated across 35 global sites, ✅ Models demonstrated strong discrimination (C-index ~0.83–0.84). ✅PPP3 performed as well as or better than existing clinical risk scores, supporting PSMA-PET–based risk stratification for guidelines, clinical decision-making, and trial design. @CalaisJeremie @DrMHofman @thomashopemd @drlouiseemmett @DrAGafita @ProfKHerrmann @ProfHadaschik @Dr_K_Rahbar @bjartell @OncoAlert 🚨 @silkegillessen @AOmlin @weoncologists #EAU26

Post attachment
Boris Hadaschik avatar
Boris Hadaschik@ProfHadaschik·Mar 29

back on X for scientific reasons because the alternative platforms unfortunately did not fulfill my expectations

NEJM avatar
⟳ Boris Hadaschik retweeted
NEJM@NEJM·2 Oct 2024

In patients with muscle-invasive bladder cancer, extended lymphadenectomy did not improve disease-free or overall survival as compared with the standard procedure and was associated with higher morbidity and mortality. Full SWOG S1011 trial results: nej.md/4dBI8UN

Post attachment
Alison Tree 💙 avatar
⟳ Boris Hadaschik retweeted
Alison Tree 💙@alison_tree·30 Sep 2024

Outstanding presentation by @drjefstathiou #ASTRO24 showing no improvement in any outcome with proton therapy for localised prostate cancer compared to photon therapy. Congratulations to all authors! 👏

Post attachmentPost attachmentPost attachment
Viktor Grünwald avatar
⟳ Boris Hadaschik retweeted
Viktor Grünwald@ViktorGruenwald·1 Oct 2024

the study did not show a meaningful difference. DFS was improved in pts with higher risk of recurrence, such as sRCC, PDL1+ or T4. Getting patient populations right is of clinical interest and leads to stronger recommendations in these groups of patients in my daily practice

Post attachment